InSysBio to take part in PAGE 2024

events
Conference
May 16, 2024

InSysBio announces its participation in the Thirty-second PAGE Meeting which is to be held from 26-28 June, 2024, at the Ergife Hotel in Rome, Italy. InSysBio will conduct a workshop on Immune Response Template (IRT) in frames of the Meeting on June 25, 2024, 11:00 – 14:00 CET. This workshop aims to demonstrate IRT templates export, edition and merge with existing projects for QSP platform development. The workshop is free of charge. Register here

Moreover, InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #15 and 4 posters in frames of the Meeting, namely:

Wednesday, June 26, 10:20-11:50:

Thursday, June 27, 09:50-11:20:

Wednesday-Friday:

Check out our Booth #15 and join our workshop at PAGE 2024!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

October 2018
MoTuWeThFrSaSu
1
1. 01 Oct 2018 12:23 InSysBio Announces Continuation of Collaboration with MedImmune for Quantitative Systems Pharmacology Modeling in Systemic Lupus Erythematosus InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.
2
1. 02 Oct 2018 14:05 InSysBio to present at ACoP9 InSysBio announces their participation at Ninth American Conference on Pharmacometrics (ACoP9), to be held October 7th to 10th, 2018, at the Loews Coronado Bay Resort near San Diego, CA. The theme of ACoP9 is “Modeling without Bounds”. InSysBio welcomes visitors at the booth #23.
3
4
5
6
7
8
9
1. 09 Oct 2018 15:29 InSysBio starts training course “Modeling for systems biology and biomedicine” InSysBio expert modelers Dr. Galina Lebedeva, Dr. Tatiana Karelina, Dr. Evgeny Metelkin and Dr. Oleg Demin will give the course “Modeling for systems biology and biomedicine” at the Faculty of bioengineering and bioinformatics, Lomonosov Moscow State University.
10
11
12
13
14
15
16
17
18
19
1. 19 Oct 2018 15:49 InSysBio to present at BiotechClub 2018 InSysBio announces their participation at BiotechClub 2018 conference to be held on October 26th at Hyatt Regency Moscow Petrovsky Park. The theme of BiotechClub 2018 is “From Systems Biology to Systems Medicine”.
20
21
22
23
24
1. 24 Oct 2018 13:49 InSysBio to present at ICSB 2018 InSysBio announces their participation at 19th International Conference on Systems Biology (ICSB 2018) to be held October 28th to November 1st, 2018 in Lyon, France.
25
26
27
28
29
30
31
    
Upcoming Events
Tags
Latest News
29.10
InSysBio to announce its collaboration with BeOne Medicines
16.10
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling
25.06
InSysBio to announce extension of collaboration with discoveric bio alpha